The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical outcomes with cumulative tumor suppressor gene (TSG) alterations in castration sensitive (CSPC) and resistant (CRPC) prostate cancer.
 
Anis Hamid
Travel, Accommodations, Expenses - AMGEN
 
Kathryn P. Gray
Stock and Other Ownership Interests - MDGN
 
Grace Shaw
No Relationships to Disclose
 
Laura E MacConaill
No Relationships to Disclose
 
Carolyn Evan
No Relationships to Disclose
 
Brandon David Bernard
No Relationships to Disclose
 
Massimo Loda
No Relationships to Disclose
 
Atish Dipankar Choudhury
Employment - LeMaitre Vascular (I)
Honoraria - Astellas Pharma; Bayer; Janssen
Research Funding - Bayer; Janssen (Inst)
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Genentech/Roche; Janssen Biotech; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen Biotech (Inst); Sanofi (Inst); Sotio (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination